We suggest you to use Compugen Ltd fundamental analysis to see if markets are presently mispricing the company. In plain English you can use it to find out if Compugen Ltd is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. . We found twenty-five available fundamental indicators for Compugen Ltd which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Compugen Ltd fundamentals including its Shares Outstanding, Revenue, EBITDA, as well as the relationship between Price to Sales and Gross Profit . Use Compugen Ltd to enhance returns of your portfolios. The stock experiences moderate upward volatility. Check odds of Compugen Ltd to be traded at S1321.1 in 30 days
Compugen Ltd Company Summary
Compugen Ltd competes with Kamada Ltd, RedHill Biopharma, BioTime, Clal Biotechnology, and Pluristem Therapeutics. Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company was incorporated in 1993 and is headquartered in Holon, Israel. Compugen Ltd operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 101 people.
Compugen Ltd Number of Employees vs Gross Profit
Compugen Ltd is rated below average in number of employees category among related companies. It is rated below average in gross profit category among related companies fabricating about 4,842 of Gross Profit per Number of Employees.
|Number of Employees|
Compugen Ltd Systematic Risk
Compugen Ltd Total Assets Over Time